Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL
1,070 views · Published 18 June 2015 · 4:25 · Indexed 4 November 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
Laurie Sehn, MD, MPH, shares the “remarkable” results from the phase III GADOLIN trial – the first randomized trial to investigate obinutuzumab plus bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding